Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (568)	5/23/1999 10:47:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1494

Neuroinvestment: Thanks for the royalty numbers on memantine. Wouldn't even 8% of the royalties still be very significant for a pico-cap like NTII? If Merz were to license memantine to a pharma for say a 25% royalty, then NTII would end up with 2% of what could easily be a billion dollar drug. One worry I've always had about memantine is if it works so well, how come it's not a big seller in Europe? Do you know if it is actually on the market and being promoted? Peter

To: NeuroInvestment who wrote (568)	5/24/1999 12:11:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

Dr. Terry, I concur with your analysis. The dementia indication will become a nice cash cow for NTII in the future. But, I, like you, don't see it as a major contributor to the success of NTII. That being said, my excitement in regard to Merz's PH III data is what it tells me about the partnership negotiations. These data have got to be impressive to companies pondering partnering with NTII/Merz. As we both metioned, the safety issue is a major one and IMHO, if there ever was any question about Memantine, this trial conclusively demonstrated its safety. Although the primary royalties from dementia will go to Merz, NTII will be the beneficiary of the strength of the partnership deal. It is my understanding that the negotiation include all indications including NTII's ADC and Diabetic Neuropathy. NTII and Merz at joined at the hip on this one and a rising tide floats both boats. So, I am very excited by the dementia data. they tell me that there is strong and convincing evidence to put before a partner and that is very good news for NTII. John de C